Drugs that contain Sirolimus

1. List of Fyarro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8911786 AADI Nanoparticle comprising rapamycin and albumin as anticancer agent
Feb, 2029

(5 years from now)

US10206887 AADI Prion free nanoparticle compositions and methods of making thereof
Apr, 2030

(7 years from now)

US10705070 AADI Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
Mar, 2036

(12 years from now)

US10973806 AADI Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin
Jun, 2036

(13 years from now)

US11497737 AADI NA
Oct, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Nov 22, 2024
Orphan Drug Exclusivity (ODE) Nov 22, 2028

Market Authorisation Date: 22 November, 2021

Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma); Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma) with a dose between about 56 mg/m2 and about 100 mg/m2 administered on days 1 and 8 of a 21-day cycle

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

FYARRO family patents

35

United States

12

Japan

9

European Union

8

Korea, Republic of

5

Portugal

5

Spain

5

Croatia

5

China

5

Lithuania

5

Canada

5

Hungary

5

Slovenia

5

Poland

5

Australia

5

Denmark

4

Russia

4

Brazil

4

New Zealand

4

Israel

3

Mexico

3

Cyprus

2

Singapore

2

EA

2

South Africa

2

Ukraine

2

RS

1

Malaysia

1

Argentina

1

Taiwan, Province of China

1

Hong Kong

1

ME

1

Chile

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic